A deep dive into the conflicting signals from Church & Dwight's stock valuation. While a discounted cash flow model suggests a significant discount, its premium P/E ratio tells a different story, leaving investors to weigh pricing power against market expectations.
A deep dive into Truist Financial's valuation suggests its current share price may not fully reflect its underlying earnings power and book value, presenting a potential opportunity for investors.
Shares of NovaGold Resources (TSX:NG) have tumbled roughly 20% in the past week, reigniting debate over the gold developer's premium valuation. While long-term shareholders have seen stellar returns, the recent pullback forces a fresh look at the risks and rewards priced into its ambitious Donlin project.
A sharp 16% weekly decline in enGene Holdings' share price puts significant pressure on its largest shareholder group—private equity firms controlling nearly half the company—raising questions about strategy and future direction amid broader market volatility.
A recent adjustment to Dexterra Group's price target by analysts, issued without detailed rationale, has stirred debate among market watchers. The move prompts a closer look at the underlying factors that may be influencing valuation models for the facilities management and workforce accommodation provider.
In a landmark move to end regulatory ambiguity, the SEC and CFTC have formally merged their 'Project Crypto' into a single rulebook. The joint initiative aims to harmonize federal oversight of crypto markets, drawing clearer lines between securities and commodities as legislative efforts advance in Congress.
While low-volatility stocks can anchor a portfolio, investors often sacrifice growth for safety. We analyze one steady performer with durable advantages and two companies where challenges may outweigh the stability premium.
While several stocks have posted impressive short-term gains, a closer look reveals a divergence between fleeting catalysts and fundamental strength. We analyze one surging name with a solid foundation and two others where caution may be warranted.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
Alphabet's self-driving subsidiary Waymo is reportedly seeking a new funding round that would value the company at approximately $110 billion, drawing fresh attention to the tech giant's ambitious bets beyond its core advertising business and the evolving landscape of autonomous vehicle investment.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.
Takeda Pharmaceutical raises its FY2025 revenue and profit guidance following resilient nine-month results and announces U.S. availability of a new ready-to-use immunoglobulin therapy for primary immunodeficiency, fueling discussions on its growth strategy amid high debt and margin pressures.
The S&P 500's 1.4% rise in January 2026 aligns with a decades-old market indicator, the 'January Barometer,' which historically signals strong full-year performance. Analysis of the past 40 years shows an 80% probability of gains through December following a positive January.
At a Singapore aviation conference, FAA Administrator Bryan Bedford publicly accepted the NTSB's findings that agency failures contributed to a mid-air collision that claimed 67 lives, vowing to implement safety reforms.
The annual Sunday Times Tax List reveals the UK's top 100 individual taxpayers paid a record £5.76bn, featuring a mix of business titans, sports stars, and entertainers, with a notable rise in contributions linked to recent fiscal policy changes.
Seagate Technology Holdings' stock surged following a strong fiscal Q2 report, fueled by robust demand from AI and data center markets. The company's revenue guidance and multi-year visibility for its advanced HAMR-based storage platform signal confidence in sustained growth, though execution risks remain.
Travere Therapeutics faces a securities fraud investigation by Robbins Geller Rudman & Dowd LLP, raising questions about the accuracy of its past disclosures. The probe casts a shadow over the company's critical transition, as it banks on its kidney drug FILSPARI to drive growth amid mounting legal and commercial pressures.
Facing rising US tariffs and global supply chain pressures, India's latest budget prioritizes strategic sectors and export support while maintaining fiscal discipline, signaling a cautious pivot toward economic resilience.
A young Australian woman on a holiday with friends in Japan's Hakuba Valley has died following a horrific incident where her backpack became entangled in a moving ski lift chair, leaving her suspended.
